全文获取类型
收费全文 | 278641篇 |
免费 | 21457篇 |
国内免费 | 8883篇 |
专业分类
耳鼻咽喉 | 2065篇 |
儿科学 | 9204篇 |
妇产科学 | 1903篇 |
基础医学 | 23821篇 |
口腔科学 | 4075篇 |
临床医学 | 30238篇 |
内科学 | 64492篇 |
皮肤病学 | 3222篇 |
神经病学 | 28010篇 |
特种医学 | 7838篇 |
外国民族医学 | 12篇 |
外科学 | 27801篇 |
综合类 | 40124篇 |
现状与发展 | 36篇 |
一般理论 | 10篇 |
预防医学 | 21508篇 |
眼科学 | 2581篇 |
药学 | 21426篇 |
229篇 | |
中国医学 | 14046篇 |
肿瘤学 | 6340篇 |
出版年
2024年 | 755篇 |
2023年 | 5418篇 |
2022年 | 9906篇 |
2021年 | 13928篇 |
2020年 | 13015篇 |
2019年 | 10046篇 |
2018年 | 9914篇 |
2017年 | 9982篇 |
2016年 | 10627篇 |
2015年 | 10395篇 |
2014年 | 19816篇 |
2013年 | 21691篇 |
2012年 | 16384篇 |
2011年 | 17703篇 |
2010年 | 14086篇 |
2009年 | 13400篇 |
2008年 | 13190篇 |
2007年 | 12938篇 |
2006年 | 11585篇 |
2005年 | 9671篇 |
2004年 | 8190篇 |
2003年 | 7028篇 |
2002年 | 5905篇 |
2001年 | 5149篇 |
2000年 | 4276篇 |
1999年 | 3690篇 |
1998年 | 3381篇 |
1997年 | 3040篇 |
1996年 | 2759篇 |
1995年 | 2520篇 |
1994年 | 2350篇 |
1993年 | 1977篇 |
1992年 | 1847篇 |
1991年 | 1641篇 |
1990年 | 1349篇 |
1989年 | 1171篇 |
1988年 | 1066篇 |
1987年 | 972篇 |
1986年 | 808篇 |
1985年 | 982篇 |
1984年 | 845篇 |
1983年 | 521篇 |
1982年 | 597篇 |
1981年 | 511篇 |
1980年 | 422篇 |
1979年 | 355篇 |
1978年 | 286篇 |
1977年 | 248篇 |
1976年 | 214篇 |
1975年 | 100篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
191.
目的 探讨非高密度脂蛋白胆固醇水平(non-HDL-C)与冠心病(CHD)患者冠状动脉病变Gensini评分的关系及临床意义。方法 对225例疑诊或既往临床诊断CHD患者予以冠状动脉造影(CAG),将造影阴性的39例作为对照组(HC组),造影阳性的186例患者诊断为CHD,结合临床特点分为心绞痛组(AP组)122例和心肌梗死组(AMI组)64例。采用Gensini评分对冠状动脉病变程度评分,测定患者全套血脂水平,探讨non-HDL-C及相关脂质成分与冠状动脉病变程度Gensini评分的相关性;同时对他汀类药物强化降脂达标,低密度脂蛋白胆固醇(LDL-C)<1.80 mmol/L的AP组患者进行non-HDL-C与冠状动脉病变程度Gensini评分的亚组分析。结果 AMI组non-HDL-C水平高于AP组及HC组,AP组non-HDL-C水平高于HC组,差异均有统计学意义(P<0.05);CHD患者non-HDL-C水平与Gensini评分呈正相关(r=0.562,P<0.05);LDL-C控制达标的AP组患者,高non-HDL-C组(≥2.60 mmol/L)比低non-HDL-C组(<2.60 mmol/L)Gensini评分明显升高,差异均有统计学意义(P<0.05)。结论 non-HDL-C与冠状动脉病变程度密切相关,non-HDL-C在评估LDL-C控制达标患者的冠状动脉病变程度及再发心血管事件风险上有一定价值,可作为LDL-C达标后心血管残余风险新的观察指标。 相似文献
192.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
193.
Hiroto Kinoshita Hitomi Nishioka Aya Ikeda Kyoko Ikoma Yoichi Sameshima Hidehisa Ohi Mizuki Tatsuno Junka Kouyama Chiaki Kawamoto Tomohiro Mitsui Yuko Tamura Yu Hashimoto Masashi Nishio Tsuyoshi Ogashiwa Yusuke Saigusa Shin Maeda Hideaki Kimura Reiko Kunisaki Kazuhiko Koike 《Journal of gastroenterology and hepatology》2019,34(11):1929-1939
194.
195.
196.
《Vaccine》2016,34(4):413-423
The essential goal of vaccination is to generate potent and long-term protection against diseases. Among different vaccine modalities, prime-boost vaccine strategies could enhance cellular and also humoral immunity in several animal models. These strategies have been applied for the development of vaccines against important infectious diseases such as HIV, SIV, HCV, HSV, and HBV indicating promising results even in clinical trials. Several factors including selection of antigen, type of vector, delivery route, dose, adjuvant, boosting regimen, the order of vector injection, and the intervals between different vaccinations influence the outcome of prime-boost immunization approaches. The reported data suggest that the prime-boost strategy as a combination of vaccines (i.e., heterologous prime-boost) may be better than a single vaccine for protection against infectious diseases. Indeed, in many cases, heterologous prime-boost can be more immunogenic than homologous prime-boost strategy. This review discusses the recent advances in prime-boost immunization strategies as well as their benefits and mechanisms of action. 相似文献
197.
Wilbert S Aronow 《Expert opinion on pharmacotherapy》2016,17(2):205-215
Introduction: It is important to know how to treat hypertension in patients with coronary artery disease (CAD). The reason for the review was to update this treatment and to discuss the 2015 American Heart Association/American College of Cardiology/American Society of Hypertension 2015 guidelines of treatment of hypertension in patients with CAD.Areas covered: Studies between 1968 and 2015 were reviewed on treatment of hypertension in patients with CAD using a Medline search, and studies between 1977 and 2015 were reported. Hypertension should be treated with beta blockers and ACE inhibitors or angiotensin receptor blockers (ARBs). Long-acting nitrates are effective antianginal and anti-ischemic drugs. Calcium-channel blockers (CCBs) may be added if angina persists despite beta blockers and long-acting nitrates. The 2015 guidelines recommend that the blood pressure should be < 140/90 mm Hg in patients aged ≤ 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years.Expert opinion: Hypertension in patients with CAD should be treated with beta blockers and ACE inhibitors or ARBs. Long-acting nitrates are effective antianginal and anti-ischemic drugs. CCBs may be added if angina persists despite beta blockers and long-acting nitrates. The blood pressure should be < 140/90 mm Hg in patients aged < 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years. 相似文献
198.
199.
200.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217